Second generation analogs of etoposide and mitomycin C.
Programs directed towards the selection of etoposide and mitomycin C analogs which exhibit superior activity, reduced toxicity and improved pharmaceutics have met with partial success. Etopofos (BMY 40481) has been chosen for development as a prodrug of etoposide possessing superior pharmaceutical properties. BMY 25067, an analog of mitomycin C, is also under development based on its improved activity profile, acceptable toxicology profile and possibly different mechanism of action.
Doyle
T W
TW
Antitumor Chemistry and Microbiology, Pharmaceutical Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492.
Vyas
D M
DM
D000818:Animals; D000970:Antineoplastic Agents; D004285:Dogs; D004354:Drug Screening Assays, Antitumor; D005047:Etoposide / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D051379:Mice; D016685:Mitomycin; D008937:Mitomycins / Q000737:chemistry / Q000494:pharmacology*; D009943:Organophosphorus Compounds / Q000737:chemistry / Q000494:pharmacology
D000970:Antineoplastic Agents; D008937:Mitomycins; D009943:Organophosphorus Compounds; D016685:Mitomycin; C061400:etoposide phosphate; D005047:Etoposide; C055172:N-7-(2-(nitrophenyldithio)ethyl)mitomycin C